¹²⁵I放射性粒子植入联合卡瑞利珠单抗治疗复发性头颈部鳞癌的临床疗效分析

Clinical Efficacy of¹²⁵I Radioactive Seed Implantation Combined with Camrelizumab in the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma

摘要

目的:本研究旨在比较¹²⁵I放射性粒子植入联合卡瑞利珠单抗与单独卡瑞利珠单抗治疗复发性头颈部鳞状细胞癌(HNSCC)的疗效和安全性,为临床治疗提供新的思路和选择。方法:回顾性分析2019年10月—2024年12月在宜昌市中心人民医院诊治的复发性HNSCC患者,根据治疗方案不同,将患者分为联合治疗组(¹²⁵I粒子植入联合卡瑞利珠单抗,n=32)和免疫治疗组(仅接受卡瑞利珠单抗,n=29),比较两组患者的无进展生存期(PFS)、总生存期(OS)及不良反应发生情况。结果:与免疫治疗组相比,联合治疗组的中位PFS(8.00个月vs 4.90个月)及中位OS(13.50个月vs 7.60个月)均显著延长(均P<0.05)。在不良反应方面,两组患者均观察到不同程度的放射、皮肤、免疫、血液及胃肠道不良反应,两组间不良反应发生率差异无统计学差异(均P>0.05)。结论:¹²⁵I放射性粒子植入联合卡瑞利珠单抗治疗复发性HNSCC可显著延长患者生存期,且安全性可接受,为复发性HNSCC患者提供了一种有前景的治疗策略。

Abstract

Objective: To compare the efficacy and safety of ¹²⁵I radioactive seed implantation combined with camrelizumab versus camrelizumab alone in the treatment of recurrent head and neck squamous cell carcinoma (HNSCC), so as to provide new ideas and options for clinical treatment. Methods: A retrospective analysis was conducted on patients with recurrent HNSCC who were diagnosed and treated in Yichang Central People's Hospital from October 2019 to December 2024. According to different treatment regimens, the patients were divided into the combined treatment group (¹²⁵I seed implantation combined with camrelizumab, n=32) and the immunotherapy group (only receiving camrelizumab, n=29). The progression-free survival (PFS), overall survival (OS) and adverse reactions of the two groups were compared. Results: Compared with the immunotherapy group, the median PFS (8.00 months vs 4.90 months) and median OS (13.50 months vs 7.60 months) in the combined treatment group were significantly prolonged (both P<0.05). In terms of adverse reactions, different degrees of radiation, skin, immune, blood and gastrointestinal adverse reactions were observed in both groups, and there was no statistically significant difference in the incidence of adverse reactions between the two groups (all P>0.05). Conclusion:¹²⁵I radioactive seed implantation combined with camrelizumab can significantly prolong the survival time of patients with recurrent HNSCC, and the safety is acceptable, providing a promising treatment strategy for patients with recurrent HNSCC.

关键词

¹²⁵I放射性粒子植入 / 卡瑞利珠单抗 / 头颈部鳞状细胞癌 / 局部复发

Key words

¹²⁵I radioactive seed implantation / camrelizumab / head and neck squamous cell carcinoma (HNSCC) / local recurrence

参考文献

[1] 郭晔, 张陈平. 复发/转移性头颈部鳞癌免疫检查点抑制剂治疗专家共识(2024年版)[J]. 中国癌症杂志, 2024, 34(4): 425-438.

[2] Dauby N. Head and neck cancer[J]. N Engl J Med, 2020, 382(20): e57.

[3] Lau A, Yang W F, Li K Y, et al. Systemic therapy in recurrent or metastatic head and neck squamous cell carcinoma— a systematic review and meta—analysis[J]. Crit Rev Oncol Hematol, 2020, 153: 102984.

[4] Cramer J D, Burtness B, Ferris R L. Immunotherapy for head and neck cancer: recent advances and future directions[J]. Oral Oncol, 2019, 99: 104460.

[5] Muzaffar J, Bari S, Kirtane K, et al. Recent advances and future directions in clinical management of head and neck squamous cell carcinoma[J]. Cancers (Basel), 2021, 13(2): 338.

[6] McDowell L, Rischin D, Gough K, et al. Health—related quality of life, psychosocial distress and unmet needs in older patients with head and neck cancer[J]. Front Oncol, 2022, 12: 834068.

[7] Hu P, Huang J W, Zhang Y L, et al. Iodine—125 seed implantation in the treatment of malignant tumors[J]. J Interv Med, 2023, 6(3): 111-115.

[8] 中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南—2024[M]. 北京: 人民卫生出版社, 2024.

[9] 杨学宁, 吴一龙. 实体瘤治疗疗效评价标准—RECIST[J]. 循证医学, 2004, 4(2): 85-90.

[10] Freites—Martinez A, Santana N, Arias—Santiago S, et al. Using the common terminology criteria for adverse events (CTCAE—version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermo Sifiliográficas (Engl Ed), 2021, 112(1): 90-92.

[11] Burtness B, Harrington K J, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE—048): a randomised, open—label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928.

[12] Svajdova M, Dubinsky P, Kazda T. Radical external beam re—irradiation in the treatment of recurrent head and neck cancer: critical review[J]. Head Neck, 2021, 43(1): 354-366.

[13] Talmor G, Trang A, Ahadiat O, et al. Anatomic danger zones of the head and neck[J]. Dermatol Surg, 2020, 46(12): 1549-1559.

[14] Budrukkar A, Guinot J L, Tagliaferri L, et al. Function preservation in head and neck cancers[J]. Clin Oncol (R Coll Radiol), 2023, 35(8): 497-506.

[15] Wei S H, Li C X, Li M Y, et al. Radioactive iodine—125 in tumor therapy: advances and future directions[J]. Front Oncol, 2021, 11: 717180.

[16] Ren S X, Chen J H, Xu X X, et al. Camrelizumab plus carboplatin and paclitaxel as first—line treatment for advanced squamous NSCLC (CameL—sq): a phase 3 trial[J]. J Thorac Oncol, 2022, 17(4): 544-557.

[17] Li Z Z, Hu Z G, Xiong X Q, et al. A review of the efficacy and safety of iodine—125 seed implantation for lung cancer treatment[J]. Cancer Treat Res Commun, 2024, 41: 100844.

[18] Wang Y X, Ma Y H, Zou L J, et al. Efficacy and safety of ¹²⁵I seed implantation in the treatment of pelvic recurrent cervical cancer following radiotherapy: a single—arm meta—analysis of Chinese patients[J]. Cancer Rep, 2024, 7(8): e2147.

[19] Sloboda R S, Liu D, Chng N, et al. Prostate size, source configuration, and dosimetry dynamics of stranded ¹²⁵I seed implants[J]. Brachytherapy, 2024, 23(5): 497-513.

[20] Zhang Z J, Wu B, Peng G, et al. Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single—arm phase 2 clinical trial[J]. Clin Cancer Res, 2022, 28(15): 3268-3276.

[21] 王俊杰, 冉维强, 姜玉良, 等. 超声引导放射性 ¹²⁵I粒子植入治疗头颈部复发或转移癌[J]. 中国微创外科杂志, 2007, 7(2): 45-47.

[22] Wei G C, Guo F X, Qu A, et al. PD—1 inhibitor maintenance therapy combined iodine—125 seed implantation successfully salvage recurrent cervical cancer after CCRT: a case report[J]. Curr Oncol, 2021, 28(6): 4577-4586.

[23] Xue G, Feng Y, Li J B. Significance of ¹²⁵I radioactive seed implantation on growth differentiation factor and programmed death receptor—1 during treatment of oral cancer[J]. World J Clin Cases, 2020, 8(5): 874-886.

[24] Wang J T, Su S, Li J, et al. Efficacy and safety of camrelizumab monotherapy and combination therapy for cancers: a systematic review and meta—analysis[J]. Front Oncol, 2021, 11: 695512.

[25] Fu X B, Qi H, Qiu Z K, et al. Outcomes of two types of iodine—125 seed delivery with metal stents in treating malignant biliary obstruction: a systematic review and meta—analysis[J]. Diagn Interv Radiol, 2023, 29(3): 509-519.

[26] Dahake S B, Uke A, Luharia A, et al. Interdisciplinary approach toward reirradiation of cancer patients[J]. Cureus, 2024, 16(7): e65750.

[27] Andersen M H. Tumor microenvironment antigens[J]. Semin Immunopathol, 2023, 45(2): 253-264.

[28] Vos J L, Elbers J B W, Krijgsman O, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma[J]. Nat Commun, 2021, 12(1): 7348.

[29] Jiang C, Wang S, Zhu L. Efficacy and safety of immunotherapy for head and neck squamous cell carcinoma: a meta—analysis of randomized clinical trials[J]. Front Oncol, 2024, 14: 1489451.

[30] Yin Q N, Wu L Y, Han L Z, et al. Immune—related adverse events of immune checkpoint inhibitors: a review[J]. Front Immunol, 2023, 14: 1167975.

[31] Ruggiero R, Di Napoli R, Balzano N, et al. Immune—related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management[J]. Expert Rev Clin Pharmacol, 2023, 16(5): 423-434.

[32] Ramos—Casals M, Sisó—Almirall A. Immune—related adverse events of immune checkpoint inhibitors[J]. Ann Intern Med, 2024, 177(2): ITC17-ITC32.

[33] Zhang Y W, Liang Y S, Liu Z Z, et al. Efficacy of radioactive ¹²⁵I seed implantation in treating inoperable or refused operation head and neck cancers[J]. J Cancer Res Ther, 2024, 20(2): 642-650.

基金资助

中央引导地方科技发展专项(2022BGE237)

宜昌市医疗卫生研究项目(A22-2-039)